EGFR and head and neck squamous cell carcinoma: With the development of monoclonal antibodies (mAb), the Food and Drug Administration (FDA) approved in 2006 the first mAb directed at the epidermal growth factor receptor (EGFR) in patients with HNSCC—cetuximab [19,20].